Experimental Hematology
Volume 38, Issue 1 , Pages 55-60 , January 2010

Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation

  • Thomas Prébet

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • Université de la Méditerranée, Marseille, France
    • INSERM UMR 599, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Patrick Ladaique

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • Centre de Thérapie Cellulaire et Génique (CTCG), Institut Paoli-Calmettes, Marseille, France
    • ,
  • Martin Ferrando

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Christian Chabannon

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • Centre de Thérapie Cellulaire et Génique (CTCG), Institut Paoli-Calmettes, Marseille, France
    • ,
  • Catherine Faucher

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Hugues De Lavallade

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Jean El-Cheikh

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Sabine Furst

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Norbert Vey

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Anne-Marie Stoppa

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Patrice Viens

      Affiliations

    • Université de la Méditerranée, Marseille, France
    • Département d' Oncologie-Médicale, Institut Paoli-Calmettes, Marseille, France
    • ,
  • Didier Blaise

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • Université de la Méditerranée, Marseille, France
    • INSERM UMR 599, Institut Paoli-Calmettes, Marseille, France
    • Drs. Blaise and Mohty share senior authorship.
    • ,
  • Mohamad Mohty

      Affiliations

    • Unité de Transplantation et de Thérapie Cellulaire (UTTC), Département d' Hématologie, Institut Paoli-Calmettes, Marseille, France
    • Université de la Méditerranée, Marseille, France
    • INSERM UMR 599, Institut Paoli-Calmettes, Marseille, France
    • Corresponding Author InformationOffprint requests to: Mohamad Mohty, M.D., Ph.D., Hematology Department, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13273 Marseille Cedex, France
    • Drs. Blaise and Mohty share senior authorship.
    • Current affiliation: Hématologie Clinique, CHU and Université de Nantes, INSERM UMR 892, Place A. Ricordeau, 44093 Nantes Cedex, France.

Received 9 July 2009 ,Revised 29 September 2009 ,Accepted 1 October 2009.

References 

  1. Mohty M, Kuentz M, Michallet M, et al. Chronic graft versus host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood. 2002;100:3128–3134
  2. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99:4234–4236
  3. Holler E, Kolb HJ, Greinix H, et al. Bleeding events and mortality in SCT patients: A retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD. Bone Marrow Transplant. 2009;43:491–497
  4. Khayyata S, Soubani AO, Bonnett M, Nassar H, Abidi MH, Al-Abbadi MA. The major autopsy findings in adult patients after hematopoietic stem cell transplantation. Ann Transplant. 2007;12:11–18
  5. Storb R. Non-myeloablative preparative regimens: experimental data and clinical practice. J Clin Oncol. 1998;241–249
  6. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  7. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18:537–546
  8. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood. 2004;103:435–441
  9. Michallet M, Bilger K, Garban F, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol. 2001;19:3340–3349
  10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  11. Faucher C, Mohty M, Vey N, et al. Bone marrow as stem cell source for allogeneic HLA-identical sibling transplantation following reduced-intensity preparative regimen. Exp Hematol. 2003;31:873–880
  12. Heldal D, Tjonnfjord G, Brinch L, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25:1129–1136
  13. Macher S, Schallmoser K, Staber PB, et al. Severe thrombocytopenia due to host-derived anti-HPA-1a after non-myeloablative allogeneic haematopoietic stem cell transplantation for multiple myeloma: A case report. Vox Sang. 2005;89:257–260
  14. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–233
  15. Ivanov V, Faucher C, Mohty M, et al. Decreased RBCTs after reduced intensity conditioning allogeneic stem cell transplantation: Predictive value of prior Hb level. Transfusion. 2004;44:501–508
  16. French DL, Fruchtman S, Mitchell WB, Coller BS, Peretz H. Evidence for megakaryocyte engraftment following reduced-intensity conditioning. Exp Hematol. 2004;32:877–880
  17. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica. 2007;92:1004–1006
  18. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–1394
  19. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113:2161–2171
  20. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: A randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641–648

PII: S0301-472X(09)00395-6

doi: 10.1016/j.exphem.2009.10.004

Experimental Hematology
Volume 38, Issue 1 , Pages 55-60 , January 2010

Article Tools

* Image Usage & Resolution